Premium
Participation in daily activities and quality of life in survivors of retinoblastoma
Author(s) -
Weintraub Naomi,
Rot Ido,
Shoshani Naomi,
Pe'er Jacob,
Weintraub Michael
Publication year - 2011
Publication title -
pediatric blood and cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.116
H-Index - 105
eISSN - 1545-5017
pISSN - 1545-5009
DOI - 10.1002/pbc.22790
Subject(s) - medicine , quality of life (healthcare) , retinoblastoma , intervention (counseling) , population , health related quality of life , gerontology , clinical psychology , pediatrics , physical therapy , psychiatry , disease , environmental health , biochemistry , chemistry , nursing , gene
Purpose To assess the participation and health‐related quality of life (HRQOL) of survivors of childhood retinoblastoma (RB). Patients and Methods Parents of 46 survivors of childhood RB between the ages of 2–18 were administered questionnaires relating to their children's participation (CFFS) and HRQOL (CHQ and PedsQL) and children were administered the PedsQL. Results of the HRQOL were compared to population‐based norms. Results The overall QOL of survivors of RB was similar to that of age norms. However, parents' rating of their children's general and emotional health was lower than that of age norms, and survivors reported lower QOL related to school. Survivors of bilateral RB participated less in daily activities and had lower emotional QOL compared to those with unilateral RB, and parents of children who had an eye enucleated reported that their children had lower self‐esteem. The level of participation was related to the perceived QOL. Conclusion Our results indicate that children who are survivors of RB have an overall QOL that is similar to their age‐peers. However, subgroups of survivors appear to have unique difficulties that require continued follow‐up and intervention. Focus should be placed on their participation in daily activities both in the community and at school. Pediatr Blood Cancer 2011;56:590–594. © 2010 Wiley‐Liss, Inc.